What key clinical parameters, biomarkers, symptoms, and patient-reported outcomes do you prioritize when determining the need for escalating therapy in RA?

What key clinical parameters, biomarkers, symptoms, and patient-reported outcomes do you prioritize when determining the need for escalating therapy in RA?

What key clinical parameters, biomarkers, symptoms, and patient-reported outcomes do you prioritize when determining the need for escalating therapy in RA?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Roy Fleischmann, MD

Roy Fleischmann, MD

Clinical Professor of Medicine
University of Texas Southwestern Medical Center at Dallas
Co-Director, Division of Rheumatology
Texas Health Presbyterian Medical Center and Co-Medical Director
Metroplex Clinical Research Center